Literature DB >> 15930167

Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences.

S Mohan1, D J Baylink.   

Abstract

Although it is well established that there is considerable inter-individual variation in the circulating levels of IGF-I in normal, healthy individuals and that a genetic component contributes substantially to this variation, the direct evidence that inter-individual variation in IGF-I contributes to differences in peak bone mineral density (BMD) is lacking. To examine if differences in IGF-I expression could contribute to peak BMD differences, we measured skeletal changes at days 23 (prepubertal), 31 (pubertal) and 56 (postpubertal) in mice with haploinsufficiency of IGF-I (+/-) and corresponding control mice (+/+). Mice (MF1/DBA) heterozygous for the IGF-I knockout allele were bred to generate +/+ and +/- mice (n=18-20 per group). Serum IGF-I was decreased by 23% (P<0.001) in mice with IGF-I haploinsufficiency (+/-) group at day 56 compared with the control (+/+) group. Femoral bone mineral content and BMD, as determined by dual energy X-ray absorptiometry, were reduced by 20% (P<0.001) and 12% respectively in the IGF-I (+/-) group at day 56 compared with the control group. The peripheral quantitative computed tomography measurements at the femoral mid-diaphysis revealed that periosteal circumference (7%, P<0.01) and total volumetric BMD (5%, P<0.05) were decreased significantly in the +/- group compared with the +/+ group. Furthermore, serum IGF-I showed significant positive correlations with both areal BMD (r=0.55) and periosteal circumference (r=0.66) in the pooled data from the +/+ and +/- groups. Our findings that haploinsufficiency of IGF-I caused significant reductions in serum IGF-I level, BMD and bone size, together with the previous findings, are consistent with the notion that genetic variations in IGF-I expression could, in part, contribute to inter-individual differences in peak BMD among a normal population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930167      PMCID: PMC2923923          DOI: 10.1677/joe.1.06141

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  28 in total

1.  Evidence that anabolic effects of PTH on bone require IGF-I in growing mice.

Authors:  N Miyakoshi; Y Kasukawa; T A Linkhart; D J Baylink; S Mohan
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

2.  Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.

Authors:  Subburaman Mohan; Charmaine Richman; Rongqing Guo; Yousef Amaar; Leah Rea Donahue; Jon Wergedal; David J Baylink
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

3.  A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels.

Authors:  Ingrid Rietveld; Joop A M J L Janssen; Albert Hofman; Huibert A P Pols; Cornelia M van Duijn; Steven W J Lamberts
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

4.  A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height.

Authors:  I Rietveld; J A M J L Janssen; E F C van Rossum; J J Houwing-Duistermaat; F Rivadeneira; A Hofman; H A P Pols; C M van Duijn; S W J Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

5.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre- and postnatal growth in two European small for gestational age populations.

Authors:  Linda B Johnston; Jovanna Dahlgren; Juliane Leger; Lars Gelander; Martin O Savage; Paul Czernichow; Kerstin Albertsson Wikland; Adrian J L Clark
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

7.  Lack of insulin-like growth factor I exaggerates the effect of calcium deficiency on bone accretion in mice.

Authors:  Yuji Kasukawa; David J Baylink; Jon E Wergedal; Yousef Amaar; Apurva K Srivastava; Rongqing Guo; Subburaman Mohan
Journal:  Endocrinology       Date:  2003-08-07       Impact factor: 4.736

Review 8.  Genetic determinants of bone mass.

Authors:  P A Baldock; John A Eisman
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

9.  Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage.

Authors:  Kazuto Hoshi; Naoshi Ogata; Takashi Shimoaka; Yasuo Terauchi; Takashi Kadowaki; Shin-Ichi Kenmotsu; Ung-Il Chung; Hedehiro Ozawa; Kozo Nakamura; Hiroshi Kawaguchi
Journal:  J Bone Miner Res       Date:  2004-02       Impact factor: 6.741

10.  Longitudinal in vivo effects of growth hormone overexpression on bone in transgenic mice.

Authors:  Felix Eckstein; Axel Weusten; Corina Schmidt; Ulrich Wehr; Rüdiger Wanke; Walter Rambeck; Eckhard Wolf; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2004-03-15       Impact factor: 6.741

View more
  28 in total

1.  25-hydroxyvitamin D, insulin-like growth factor-I, and bone mineral accrual during growth.

Authors:  M E Breen; E M Laing; D B Hall; D B Hausman; R G Taylor; C M Isales; K H Ding; N K Pollock; M W Hamrick; C A Baile; R D Lewis
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

2.  Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion.

Authors:  Kristen E Govoni; Jon E Wergedal; Lore Florin; Peter Angel; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2007-08-23       Impact factor: 4.736

3.  Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions.

Authors:  Shoshana Yakar; Ernesto Canalis; Hui Sun; Wilson Mejia; Yuki Kawashima; Philip Nasser; Hayden-William Courtland; Valerie Williams; Mary Bouxsein; Clifford Rosen; Karl J Jepsen
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

Review 4.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

Review 5.  Insulin-like growth factors: actions on the skeleton.

Authors:  Shoshana Yakar; Haim Werner; Clifford J Rosen
Journal:  J Mol Endocrinol       Date:  2018-04-06       Impact factor: 5.098

Review 6.  Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.

Authors:  Yongyong Yan; Liping Wang; Linhu Ge; Janak L Pathak
Journal:  Curr Osteoporos Rep       Date:  2020-02       Impact factor: 5.096

7.  Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice.

Authors:  Kristen E Govoni; Jon E Wergedal; Robert B Chadwick; Apurva K Srivastava; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-23       Impact factor: 4.310

8.  Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice.

Authors:  V E DeMambro; D R Clemmons; L G Horton; M L Bouxsein; T L Wood; W G Beamer; E Canalis; C J Rosen
Journal:  Endocrinology       Date:  2008-02-14       Impact factor: 4.736

9.  Effects of alcohol on skeletal response to growth hormone in hypophysectomized rats.

Authors:  Russell T Turner; Clifford J Rosen; Urszula T Iwaniec
Journal:  Bone       Date:  2009-10-30       Impact factor: 4.398

10.  Proportionate Dwarfism in Mice Lacking Heterochromatin Protein 1 Binding Protein 3 (HP1BP3) Is Associated With Alterations in the Endocrine IGF-1 Pathway.

Authors:  Benjamin P Garfinkel; Shiri Arad; Phuong T Le; Michael Bustin; Clifford J Rosen; Yankel Gabet; Joseph Orly
Journal:  Endocrinology       Date:  2015-09-24       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.